Advertisement

Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy

  • Runa Speer
  • Julia Wulfkuhle
  • Virginia Espina
  • Robyn Aurajo
  • Kirsten H. Edmiston
  • Lance A. Liotta
  • Emanuel F. PetricoinIII
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 610)

The practice of medicine has always aimed at individualized treatment of disease. The relationship between patient and physician has always been a personal one, and the physician's choice of treatment has been intended to be the best fit for the patient's needs. The necessary pooling/grouping of disease families and their assignment to a number of drugs or treatment methods has, consequently, led to an increase in the number of effective therapies. However, given the heterogeneity of most human diseases, and cancer specifically, it is currently impossible for the treating clinician to effectively predict a patient's response and outcome based on current technologies, much less the idiosyncratic resistances and adverse effects associated with the limited therapeutic options.

Keywords

Laser Capture Microdissection Functional Executive Antibody Array Limited Therapeutic Option Amplification Chemistry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aebersold, R., Goodlett, D. R. (2001) Mass spectrometry in proteomics. Chem Rev 101(2), 269–95.PubMedCrossRefGoogle Scholar
  2. Bobrow, M. N., Shaughnessy, K. J., and Litt, G. J. (1991) Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods. 137(1), 103–12.PubMedCrossRefGoogle Scholar
  3. Brennan, D. J. et al. (2005) Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther 5, 1069–1083.PubMedCrossRefGoogle Scholar
  4. Chakravarti, D. N., Chakravarti, B., Moutsatsos, I. (2002) Informatic tools for proteome profiling.Biotechniques Suppl 4–10: 12–5.Google Scholar
  5. Emmert-Buck, M. R., et al. (1996) Laser capture microdissection. Science 274, 998–1001 (1996).PubMedCrossRefGoogle Scholar
  6. Giltrane, J. M. & Rimm, D. L. (2005) Technology insight: identification of biomarkers with tissue microarray technology. Nature Clin Pract Oncol 1, 104–111.CrossRefGoogle Scholar
  7. Grubb, R. L., et al. (2003) Signal pathway profiling of prostate cancer using reverse phase protein microarrays. Proteomics 3, 2142–2146.PubMedCrossRefGoogle Scholar
  8. Haab, B. B., Dunham, M. J., and Brown, P. O. (2001) Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2(2).Google Scholar
  9. Humphery-Smith, I., Wischerhoff, E., and Hashimoto, R. (2002) Protein arrays for assessment of target selectivity. Drug Discovery World 4(1), 17–27.Google Scholar
  10. Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P. J., Young, L., Wulfkuhle, J., and Petricoin, E. F. (2003) Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317–25.PubMedCrossRefGoogle Scholar
  11. Macbeath, G. (2002) Protein microarrays and proteomics. Nat Genet. 32 Suppl(526–32).Google Scholar
  12. Paweletz, C. P., Charboneau, L., Roth, M. J., Bichsel, V. E., Simone, N. L., Chen, T., Han, N., Gillespie, J. W., Emmert-Buck, M., Petricoin, E. F., and Liotta, L. A. (2001) Reverse phase proteomic microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. Apr 12;20(16), 1981–9.PubMedCrossRefGoogle Scholar
  13. Panisko, E. A., Conrads, T. P., Goshe, M. B., Veenstra, T. D. (2002) The postgenomic age: characterization of proteomes. Exp Hematol 30(2), 97–107.PubMedCrossRefGoogle Scholar
  14. Petricoin, E., Wulfkuhle, J., Espina, V., and Liotta, L. A. (2004) Clinical proteomics: revolutionizing disease detection and patient-tailoring therapy. J Proteome Res. 3(2), 209–17.PubMedCrossRefGoogle Scholar
  15. Petricoin III, E. F., et al. (2005) Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23, 3614–3621.PubMedCrossRefGoogle Scholar
  16. Segal, E., Friedman, N., Kaminski, N., Regev, A. & Koller, D. (2005) From signatures to models: understanding cancer using microarrays. Nat Genet 37 Suppl., S38–S45.PubMedCrossRefGoogle Scholar
  17. Shankavaram, U. T., Reinhold, W. C., Nishizuka, S., Major, S., Morita, D., Chary, K. K., Reimers, M. A., Scherf, U., Kahn, A., Dolginow, D., Cossman, J., Kaldjian, E. P., Scudiero, D. A., Petricoin, E., Liotta, L., Lee, J. K., Weinstein, J. N. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. Mar 5.Google Scholar
  18. Sheehan, K. M., et al. (2005) Use of reverse-phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4, 346–355.PubMedCrossRefGoogle Scholar
  19. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S. D., Willis, J., Dawson, D., Willson, J. K., Gazdar, A. F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B. H., Bachman, K. E., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., Velculescu, V. E. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268–74.PubMedCrossRefGoogle Scholar
  20. Wilson, D. S. and Nock, S. (2003) Recent developments in protein microarray technology. Angew Chem Int Ed Engl 42(5), 494–500.PubMedCrossRefGoogle Scholar
  21. Wulfkuhle, J. D., et al. (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3, 2085–2090.PubMedCrossRefGoogle Scholar
  22. Wulfkuhle, J. D., Edmiston, K. H., Liotta, L. A., Petricoin, E. F. (2006) Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. May;3(5), 256–68.PubMedCrossRefGoogle Scholar
  23. Zha, H., et al. (2004) Similarities of pro-survival signals in Bcl-2-positive and Bcl-2-negative follicular lymhomas identified by reverse phase protein microarray. Lab Invest 84, 235–244.PubMedCrossRefGoogle Scholar
  24. Zhu, H. and Snyder, M. (2003) Protein chip technology. Curr Opin Chem Biol 7(1), 55–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Runa Speer
    • 1
  • Julia Wulfkuhle
    • 2
  • Virginia Espina
    • 2
  • Robyn Aurajo
    • 2
  • Kirsten H. Edmiston
    • 3
  • Lance A. Liotta
    • 2
  • Emanuel F. PetricoinIII
    • 2
    • 4
  1. 1.University of Tübingen, Faculty of Medicine, Department of Obstetrics and GynecologyTübingenGermany
  2. 2.Center for Applied Proteomics and Molecular MedicineGeorge Mason UniversityManassas
  3. 3.Department of SurgeryInova Fairfax Hospital Cancer CenterFalls Church
  4. 4.Center for Applied Proteomics and Molecular MedicineGeorge Mason UniversityManassas

Personalised recommendations